Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding
Edward Romond
Edward Romond, University of Kentucky, LexingtonMore data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
Related Episodes
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F
Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro